Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric04
2023-507963-20-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall survival. Planned start Aug 2021; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-507963-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507963-20-00.